Evicenter
P&T meetings

Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
Last updated
65 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic colorectal cancer

Economic burden and healthcare resource utilization

4 evidence topics · 4 sources

Metastatic colorectal cancer treatment costs: systematic review

“Costs of treating metastatic colorectal cancer varied because of the heterogeneity of treatment.” (opens the source at this quote in a new tab)

“Studies reported average costs ranged from $12,346 to $293,461.” (opens the source at this quote in a new tab)

Cost concentration in regimens containing biological agents

“Studies that treated patients with biological agents demonstrated costs ranging from $80,000 to almost $300,000.” (opens the source at this quote in a new tab)

“The studies included in this systematic review demonstrate a rising cost of treating mCRC over the past 20 years.” (opens the source at this quote in a new tab)

“the economic burden of treating patients with mCRC is substantial, particularly after the introduction of expensive biological agents such as cetuximab, bevacizumab, and panitumumab.” (opens the source at this quote in a new tab)

Major financial hardship in metastatic colorectal cancer

“Cumulative incidence of MFH at 12 months was 71.3% (95% confidence interval = 65.7% to 76.1%).” (opens the source at this quote in a new tab)

“A total of 380 patients (median age = 59.9 years) were enrolled; 77.7% were White, 98.0% insured, and 56.5% had annual income of $50 000 or less.” (opens the source at this quote in a new tab)

Comparator and disease-state studies: third-line treatment discontinuation and cost effectiveness

“Among 82 patients” (opens the source at this quote in a new tab)

“Analyses were conducted from the US Medicare payer perspective” (opens the source at this quote in a new tab)

“The ICER was US$518,000 per QALY gained.” (opens the source at this quote in a new tab)